索 引 号 bm56000001/2023-00010372 分 类 叶湘武、丛树芬、欧阳艳丽、毕元、马贤鹏、张军国、刘莉敏： 发布机构 发文日期 1694562069000 名 称 关于对叶湘武、丛树芬、欧阳艳丽、毕元、马贤鹏、张军国、刘莉敏采取出具警示函行政监 管措施的决定 文 号 主 题 词 关于对叶湘武、丛树芬、欧阳艳丽、毕元、马贤鹏、张军国、刘莉敏 采取出具警示函行政监管措施的决定 据查，2017年-2019年间，湖南景峰医药股份有限公司（以下简称"景峰医 药"）通过上海景峰制药有限公司等子公司签订虚假工程项目、咨询服务等合 同，套用景峰医药资金，在工资薪酬之外，向上市公司有关人员额外发放团建 费、业务维护费等，将部分支出记入"在建工程""固定资产"科目，造成虚增资 产、利润。2017年-2019年，景峰医药虚增资产、利润分别为490.34万元、 1,751.62万元、758.68万元。上述支出中，有1,376.76万元来源于公司募投资 金，列支在募投项目中，募集资金管理和使用不规范。 上述行为违反了《上市公司信息披露管理办法》（证监会令第40号）第三 条、第五十八条、《上市公司监管指引第2号—上市 ...

湖南景峰医药股份有限公司： 据查，你公司存在以下问题： 1.通过上海景峰制药有限公司等子公司签订虚假工程项目、咨询服务等合 同，套用公司资金，在工资薪酬之外，向公司有关人员额外发放团建费、业务 维护费等，将部分支出记入"在建工程""固定资产"科目，造成虚增资产、利 润。2017年-2019年，景峰医药虚增资产、利润分别为490.34万元、1,751.62万 元、758.68万元。上述支出中，有1,376.76万元来源于公司募投资金，列支在 募投项目中，募集资金管理和使用不规范。 索 引 号 bm56000001/2023-00010371 分 类 发布机构 发文日期 1694561977000 名 称 关于对湖南景峰医药股份有限公司采取责令改正行政监管措施的决定 文 号 主 题 词 关于对湖南景峰医药股份有限公司采取责令改正行政监管措施的决定 2.2017年，你公司投资云南联顿医院有限公司（以下简称"云南联顿"）时 的《增资协议》显示，云南联顿原股东安泉、陈静、肖琨、吴洁芳、阿灼辉等 人对云南联顿业绩作出承诺，云南联顿2018年至2020年净利润分别不低于 1,928万元、2,120万元和2,332万元，三年 ...

证券代码：000908 证券简称：景峰医药 公告编号：2023-034 湖南景峰医药股份有限公司 关于收到湖南证监局行政监管措施决定书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 湖南景峰医药股份有限公司（以下简称"景峰医药"或"公司"）于近日收到 中国证券监督管理委员会湖南监管局（以下简称"湖南证监局"）下发的《关于对 湖南景峰医药股份有限公司采取责令改正行政监管措施的决定》（[2023]35 号）及 《关于对叶湘武、丛树芬、欧阳艳丽、毕元、马贤鹏、张军国、刘莉敏采取出具警 示函行政监管措施的决定》（[2023]36 号），现将具体情况公告如下： 一、行政监管措施决定书的具体内容 （一）《关于对湖南景峰医药股份有限公司采取责令改正行政监管措施的决定》 （[2023]35 号） "湖南景峰医药股份有限公司： 据查，你公司存在以下问题： 1．通过上海景峰制药有限公司等子公司签订虚假工程项目、咨询服务等合同， 套用公司资金，在工资薪酬之外，向公司有关人员额外发放团建费、业务维护费等， 将部分支出记入"在建工程""固定资产"科目，造成虚增资产、利润。2017 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥380,521,926.69, a decrease of 5.34% compared to ¥402,009,285.92 in the same period last year[23]. - The net loss attributable to shareholders was ¥12,845,641.09, representing a 12.07% increase in loss from ¥11,462,480.25 in the previous year[23]. - The net cash flow from operating activities decreased by 71.15% to ¥17,119,291.73, down from ¥59,346,453.34 in the same period last year[23]. - The basic and diluted earnings per share were both -¥0.0146, a decline of 12.31% from -¥0.0130 in the previous year[23]. - The total assets at the end of the reporting period were ¥1,461,349,834.82, a decrease of 0.49% from ¥1,468,474,402.63 at the end of the previous year[23]. - The net assets attributable to shareholders decreased by 7.00% to ¥165,469,083.60 from ¥177,927,696.16 at the end of the previous year[23]. - The company reported a significant increase in the loss from non-recurring gains and losses, with a net profit of -¥19,417,289.20 compared to -¥13,461,960.78 in the previous year, marking a 44.24% increase in loss[23]. - The weighted average return on net assets was -7.48%, a decrease of 3.67% from -3.81% in the previous year[23]. - The company reported a total non-operating income of 6,571,648.11, after accounting for government subsidies of 9,754,758.50 and other non-operating expenses of -4,675,930.79[28]. - The company’s financial expenses decreased by 23.79% to ¥18,947,109.67, primarily due to reduced borrowing[46]. - The company’s cash and cash equivalents decreased by 239.31%, resulting in a net decrease of ¥15,618,678.19, influenced by various operational factors[48]. - The company reported a net cash outflow from investing activities of -9,447,401.03 yuan, compared to a net inflow of 84,541,569.51 yuan in the same period last year[189]. - The company incurred financial expenses of 10,962,658.77 yuan, down from 13,302,126.30 yuan in the previous year, showing a reduction of about 17.5%[185]. Operational Strategy - The company operates in the pharmaceutical manufacturing industry, focusing on cardiovascular, oncology, rheumatology, pediatrics, digestive system, burn treatment, anti-infection, and medical device product lines[30]. - The procurement model emphasizes risk control, cost minimization, and quality assurance, with a centralized approach to sourcing raw materials and supplies[32]. - The production model is based on sales-driven planning, ensuring production aligns with marketing and inventory data, while adhering to strict GMP standards[33]. - The sales strategy combines direct sales with academic marketing, enhancing brand image and expanding market reach, including efforts in third-party and OTC markets[33]. - The company employs a collaborative R&D model, focusing on key areas for rapid breakthroughs and maintaining partnerships with global pharmaceutical companies for innovation[34]. - Future R&D efforts will target significant diseases, with a focus on incremental innovation and early planning around patent expirations[34]. - The company is enhancing its subsidiary management to optimize operational performance and reduce costs amid a changing market environment[44]. - The company aims to reduce operational costs by 10% through efficiency improvements and automation initiatives by the end of 2023[84]. Research and Development - The company has a diverse product pipeline, including unique products such as the heart and brain capsule and various oncology injections, with a focus on national insurance categories[30]. - Research and development investment increased significantly by 242.58%, reaching ¥47,349,835.09, as the company intensified its focus on ongoing projects[46]. - The company is advancing its research and development pipeline, focusing on high-end formulations like liposomes and nanoemulsions, and aims for dual submissions in the US and China[41]. - The company is conducting clinical research on Xinnaoning capsules as part of a national key research project, which may expand its market presence[38]. - The company plans to launch new products to enrich its existing product pipeline, including those in the ophthalmic and pain relief categories[36]. - The company focuses on independent research and development as well as authorized introduction of products, facing high investment and long approval cycles in new drug development[65]. - The company has set a performance guidance for the next quarter, expecting a revenue growth of 5% to 10%[200]. Market Expansion - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by Q4 2023[84]. - A strategic acquisition of a local biotech firm is in progress, which is anticipated to enhance the company's R&D capabilities and add 150 million RMB in annual revenue[84]. - The company is exploring potential mergers and acquisitions to strengthen its market position[200]. - The overall market outlook remains positive, with anticipated growth driven by increasing demand for healthcare products[200]. Environmental Compliance - The company adheres to national and local environmental protection laws and standards, ensuring compliance in wastewater and emissions management[75]. - The company reported that its wastewater discharge parameters are within the prescribed limits, demonstrating compliance with environmental standards[76]. - The company has maintained compliance with all wastewater and air emission standards, indicating effective environmental management practices[78]. - The company is focused on continuous improvement in its environmental performance and compliance with regulatory standards[79]. - The company has established a comprehensive waste management system to track and report emissions accurately[80]. - The company has implemented measures to ensure that all emissions from its facilities are within the permissible limits, demonstrating commitment to environmental standards[80]. - The company has established emergency response plans for environmental incidents, which have been filed with the relevant environmental protection departments[95]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 70,951[141]. - The total number of unrestricted shares increased from 781,974,538 to 788,907,887, an increase of 6,933,349 shares[138]. - The largest shareholder, China Great Wall Asset Management Co., holds 113,680,665 shares, representing 12.92% of total shares[145]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[147]. - The company has no preferred shares or corporate bonds outstanding as of the reporting period[151][156]. Legal and Compliance Issues - The company reported a major litigation case involving a share transfer dispute with a claim amount of 9,090,000 yuan[108]. - The company has not engaged in any significant related party transactions during the reporting period[110]. - The semi-annual financial report has not been audited[105]. - The company maintains a good integrity status with no significant overdue debts or unfulfilled court judgments[109].

湖南景峰医药股份有限公司2023年半年度报告全文 湖南景峰医药股份有限公司 2023 年半年度报告 2023 年 8 月 ...

湖南景峰医药股份有限公司独立董事 (此页无正文，为《湖南景峰医药股份有限公司独立董事关于第八届董事会第 二十四次会议相关事项的独立意见》之签署页) 根据中国证监会《上市公司监管指引第 8 号——上市公司资金往来、对外 担保的监管要求》（证监会公告〔2022〕26 号）等相关规定，我们对公司 2023 年半年度控股股东及其他关联方占用公司资金及公司对外担保情况进行了核查： 1、截至本报告期末，公司未发生也不存在以前期间发生并延续到报告期的 控股股东及其他关联方占用公司资金的情况。 2、报告期内，公司不存在为控股股东及其关联方提供担保的情况，不存在 为子公司之外的第三方提供担保的情况，也不存在以前年度累计至今的除子公司 之外的对外担保，对子公司的担保已履行必要程序，合法合规。 （以下无正文） 关于第八届董事会第二十四次会议相关事项的独立意见 根据中国证监会《上市公司独立董事规则》、《上市公司治理准则》和深圳 证券交易所《股票上市规则》以及《公司章程》等有关规定,我们作为湖南景峰 医药股份有限公司（以下简称"公司"）之独立董事,对 2023 年 8 月 24 日召开 的公司第八届董事会第二十四次会议相关事项发表如下 ...

湖南景峰医药股份有限公司 | | 资金占用方名 | 占用方与上 | 上市公司核 | 2023 | 年期初 | 2023 年半年 度占用累计 | 2023 年半年 度占用资金 | 2023 年半年 | 2023 | 年半年 占用形成原 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | 市公司的关 | 算的会计科 | | 占用资金余 | | | 度偿还累计 | | 期末占用资 | 占用性质 | | | 称 | | | | | 发生金额（不 | 的利息（如 | | | 因 | | | | | 联关系 | 目 | | 额 | 含利息） | 有） | 发生金额 | 金余额 | | | | 控股股东、实际控制人及 | | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | | 小计 | - | - | - | | | | | | | | | | 前控股股东、实际控制人 | | | | | | | | | | | | | 及其附属企业 | ...

Financial Performance - The company's operating revenue for 2022 was ¥840,657,161.99, representing a 3.63% increase from ¥811,183,491.16 in 2021[20] - The net profit attributable to shareholders was -¥128,162,925.43, an improvement of 21.69% compared to -¥163,660,189.96 in the previous year[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥149,721,920.08, showing a significant reduction of 68.63% from -¥477,230,162.44 in 2021[20] - The basic and diluted earnings per share were both -¥0.1457, reflecting a 21.67% improvement from -¥0.186 in 2021[20] - Total assets at the end of 2022 were ¥1,468,474,402.63, a decrease of 18.07% from ¥1,792,299,532.27 at the end of 2021[20] - The net assets attributable to shareholders decreased by 41.93% to ¥177,927,696.16 from ¥306,389,794.75 in 2021[20] - The cash flow from operating activities was ¥123,266,701.34, a slight decrease of 0.46% from ¥123,834,599.70 in 2021[20] - The company reported a significant reduction in non-operating income, with operating revenue after deductions amounting to ¥818,141,263.01[21] Quarterly Performance - In Q1 2022, the company's operating revenue was approximately ¥181.4 million, while in Q4 2022, it increased to approximately ¥228.8 million, showing a growth of about 26% quarter-over-quarter[25] - The net profit attributable to shareholders in Q2 2022 was a loss of approximately ¥14.8 million, which worsened to a loss of approximately ¥98.4 million in Q4 2022, indicating a significant decline in profitability[25] - The cash flow from operating activities in Q2 2022 was approximately ¥55.9 million, but dropped to approximately ¥10.6 million in Q4 2022, reflecting a decrease of about 81%[25] Industry Context - The pharmaceutical industry in China is undergoing significant reforms, with over 300 policies released in 2022 aimed at improving healthcare delivery and drug procurement processes[32] - The company is facing risks related to product bidding failures and is actively working to enhance product categories and accelerate R&D efforts to mitigate these risks[93] - The company anticipates ongoing price reductions in the pharmaceutical market due to stricter healthcare cost controls, which may lead to a decline in average profit margins[94] Product Development and R&D - The company maintains a diverse product pipeline, including unique products in cardiovascular, oncology, and pediatric fields, which are critical for future growth[33] - The company emphasizes self-research and collaborative development in its R&D model, integrating resources across its subsidiaries to enhance innovation and project outcomes[37] - The company aims to expand its product pipeline continuously, with several products already receiving clinical approval or undergoing clinical research[41] - The R&D center aims to establish a leading research and development system, with ongoing projects including the Phase III clinical trial for a new drug and several consistency evaluations for injection products[88] Marketing and Sales Strategy - The sales model is based on a responsibility system for regional sales managers, combining multi-product matrix management, which has significantly improved per capita productivity and strengthened academic promotion efforts[36] - The company has established a marketing network covering all 31 provinces, cities, and autonomous regions in China, enhancing its sales model to include private hospitals and grassroots medical markets[46] - The marketing strategy focuses on deepening market penetration and enhancing brand value through a combination of direct sales and partnerships[89] Financial Management and Governance - The company has not reported any significant discrepancies between financial reports prepared under international and Chinese accounting standards[22] - The company has established strict production management systems and implemented dynamic monitoring of production processes to ensure compliance with GMP standards, resulting in stable and qualified product quality[36] - The company emphasizes transparent information disclosure, adhering to regulations and ensuring timely and accurate reporting[103] - The board of directors operates with a reasonable professional structure and adheres to legal and regulatory requirements[102] Environmental Compliance and Sustainability - The company has established a comprehensive environmental protection compliance framework, adhering to multiple national and local environmental standards[146] - The company is committed to continuous improvement in its environmental performance, aligning with industry best practices and regulatory expectations[153] - The company has implemented various pollution control technologies, including activated carbon adsorption and alkaline liquid absorption, to ensure compliance with environmental standards[164] Employee Management and Compensation - The total number of employees at the end of the reporting period is 645, with 46 in the parent company and 599 in major subsidiaries[129] - The professional composition includes 278 production personnel, 41 sales personnel, 170 technical personnel, 29 financial personnel, and 127 administrative personnel[129] - The company has a differentiated compensation strategy, ensuring competitive salary levels while controlling labor costs[130] Future Outlook and Strategic Initiatives - The company plans to double the number of hospitals covered by its products in the next five years, currently exceeding 10,000 hospitals[47] - The company is exploring new media and e-commerce technologies to enhance market penetration and reach end consumers more effectively[36] - The company plans to enhance its production capabilities by expanding its CDMO business and leveraging existing production lines for various drug formulations[87]

Financial Performance - The company's operating revenue for 2022 was ¥840,657,161.99, representing a 3.63% increase compared to ¥811,183,491.16 in 2021[20] - The net profit attributable to shareholders was -¥128,162,925.43, an improvement of 21.69% from -¥163,660,189.96 in the previous year[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥149,721,920.08, showing a significant reduction of 68.63% from -¥477,230,162.44 in 2021[20] - The basic earnings per share for 2022 was -¥0.1457, which is a 21.67% improvement from -¥0.186 in 2021[20] - Total assets at the end of 2022 were ¥1,468,474,402.63, a decrease of 18.07% from ¥1,792,299,532.27 at the end of 2021[20] - The net assets attributable to shareholders decreased by 41.93% to ¥177,927,696.16 from ¥306,389,794.75 in 2021[20] - The operating cash flow net amount was ¥123,266,701.34, a slight decrease of 0.46% from ¥123,834,599.70 in the previous year[20] - The weighted average return on equity was -52.93%, worsening from -39.18% in 2021[20] Business Operations - The company has maintained its main business focus in the pharmaceutical manufacturing industry, with no significant changes reported in its business operations[33] - The product pipeline includes unique offerings in various therapeutic areas, such as cardiovascular, oncology, and anti-infection, with several products being exclusive to the company[33] - The company is actively involved in research and development of biopharmaceutical technologies and has a diverse range of products across multiple medical fields[33] - The company has implemented a procurement model focused on risk control, cost minimization, and quality assurance to enhance operational efficiency[34] - The company has over 20 production lines certified by GMP, covering various dosage forms including large and small volume injections, freeze-dried powder injections, and oral preparations[39] Market and Sales Strategy - The company emphasizes a sales model that combines self-operated teams with outsourcing and agency partnerships, enhancing academic marketing efforts[36] - The company has established a strong market presence in the orthopedic field, being the exclusive selected supplier in the Southwest Five Provinces for sodium hyaluronate injections[42] - In the oncology sector, the company secured the first position in the national volume-based procurement for irinotecan injections in several regions including Shanghai and Jiangsu[42] - The company is actively exploring new media and e-commerce technologies for market expansion, aiming to penetrate deeper into the terminal market[36] Research and Development - The company has a robust R&D model that integrates self-research and collaborative development, focusing on key areas for rapid breakthroughs[37] - The company aims to expand its product pipeline continuously, with several products already in clinical trials or having received clinical approval[41] - The company has achieved significant progress in the generic drug sector, with multiple products, including injection forms of gemcitabine and irinotecan, successfully passing consistency evaluation registration[44] - The company is focusing on cost reduction and efficiency improvement by streamlining its workforce and enhancing performance assessments of subsidiaries[48] Environmental Compliance - The company has established a comprehensive pollution control system to manage and treat emissions effectively, ensuring environmental compliance[160] - The company has implemented various environmental protection measures, including waste gas treatment systems, which have faced operational challenges in 2022[143] - The company reported a total environmental governance expenditure of approximately 800,000 RMB in 2022, with an environmental protection tax payment of 522.45 RMB[164] - The company has successfully maintained compliance with wastewater discharge standards for COD at 25.9751 mg/L, against a limit of 100 mg/L[159] Governance and Compliance - The company maintains an independent governance structure, ensuring no interference from the controlling shareholder in decision-making processes[101] - The company emphasizes transparency in information disclosure, adhering to regulations and ensuring timely and accurate reporting[103] - The board of directors operates with a reasonable professional structure and adheres to legal and regulatory requirements[102] - The company has established a robust internal control system to enhance management and compliance[104] Future Outlook - The company plans to enhance its production capabilities by expanding its CDMO business and utilizing existing production lines to maximize capacity[87] - The company is actively pursuing internationalization, with plans for cGMP upgrades and dual submissions for major products in both China and the U.S.[45] - The company plans to enter the European market by Q3 2023, targeting a revenue contribution of 10% from this region[151] - The company expects a revenue growth of 15% for the next fiscal year, projecting a target revenue of 1.725 billion CNY[151]

Financial Performance - The company's revenue for Q1 2023 was ¥176,056,130.03, a decrease of 2.95% compared to ¥181,402,884.35 in the same period last year[3] - Net profit attributable to shareholders decreased by 61.69% to ¥1,278,629.96 from ¥3,338,005.22 year-on-year[3] - Basic and diluted earnings per share fell by 60.53% to ¥0.0015 from ¥0.0038 in the same period last year[3] - Net profit for Q1 2023 was CNY 8,743,250.95, a decline of 28.5% from CNY 12,166,960.10 in Q1 2022[15] - The company reported a decrease in basic and diluted earnings per share to CNY 0.0015 from CNY 0.0038 in the previous year[16] Cash Flow - The net cash flow from operating activities increased significantly by 295.27% to ¥13,623,933.97 compared to ¥3,446,754.01 in the previous year[3] - Cash flow from operating activities increased to CNY 202,370,713.36 in Q1 2023, compared to CNY 186,693,029.70 in Q1 2022, representing an increase of 8.9%[17] - The net cash flow from operating activities for Q1 2023 was ¥13,623,933.97, an increase from ¥3,446,754.01 in Q1 2022, representing a significant improvement[18] - Total cash inflow from operating activities amounted to ¥207,907,529.55, compared to ¥195,527,717.11 in the same period last year[18] - The company paid ¥30,851,865.05 in taxes during the quarter, compared to ¥8,052,906.25 in the previous year, reflecting increased tax obligations[18] - Cash received from other operating activities was ¥5,536,816.19, showing a decrease from ¥8,834,687.41 year-over-year[18] - The company incurred cash payments to employees totaling ¥36,266,206.23, a decrease from ¥39,982,668.05 in Q1 2022[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,474,206,115.16, reflecting a slight increase of 0.39% from ¥1,468,474,402.63 at the end of the previous year[3] - The company’s total assets amounted to CNY 1,474,206,115.16, a slight increase from CNY 1,468,474,402.63 at the end of the previous quarter[13] - Total liabilities were reported at CNY 1,251,235,538.73, a decrease from CNY 1,253,645,942.02 in the previous quarter[13] - The company’s equity attributable to shareholders increased to CNY 178,899,747.20 from CNY 177,927,696.16 in the previous quarter[13] Operating Costs and Income - Total operating costs for Q1 2023 were CNY 168,775,870.62, down from CNY 170,714,929.26 in the same period last year, reflecting a reduction of 1.1%[14] - The company reported a significant decrease in other income by 88.90%, primarily due to lower government subsidies compared to the previous year[6] Research and Development - Research and development expenditures capitalized increased by 30.14%, reflecting the company's commitment to innovation[6] - Research and development expenses for Q1 2023 were CNY 5,099,494.09, slightly up from CNY 4,875,944.05 in Q1 2022[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 73,540[7] Cash Flow from Investing and Financing Activities - The net cash flow from investing activities was -¥5,259,594.09, a decrease from ¥84,691,218.51 in Q1 2022, indicating a shift in investment strategy[19] - Cash inflow from financing activities totaled ¥138,000,000.00, while cash outflow was ¥147,210,453.05, resulting in a net cash flow of -¥9,210,453.05[19] - The company’s cash flow from financing activities included cash received from borrowings of ¥138,000,000.00, indicating reliance on debt financing[19] - The ending balance of cash and cash equivalents was ¥180,549,539.74, down from ¥151,688,057.20 in Q1 2022[19] - The company reported cash inflow from the disposal of fixed assets and other long-term assets of ¥1,129,800.00, compared to ¥900,800.00 in the previous year[18]